01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Background
Methods
Study population
Study covariates
Aspiration pneumonia
Statistical analysis
Results
Background
|
n (%)
|
---|---|
Age
|
|
< 65 years
|
149 (49)
|
≥ 65 years
|
156 (51)
|
Gender
|
|
Male
|
266 (87)
|
Female
|
39 (13)
|
ECOG performance status
|
|
0
|
181 (59)
|
1
|
109 (36)
|
2
|
12 (4)
|
3
|
3 (1)
|
Body mass index
|
|
< 18.5
|
46 (15)
|
18.5–25
|
199 (65)
|
≥ 25
|
60 (20)
|
Primary site
|
|
Larynx
|
45 (15)
|
Nasopharynx
|
38 (12)
|
Hypopharynx
|
112 (37)
|
Nasal sinus
|
17 (6)
|
Oropharynx
|
79 (26)
|
Oral cavity
|
14 (5)
|
T-classification
|
|
1
|
28 (9)
|
2
|
110 (36)
|
3
|
66 (66)
|
4
|
101 (33)
|
N-classification
|
|
0
|
63 (21)
|
1
|
39 (13)
|
2a
|
3 (1)
|
2b
|
126 (41)
|
2c
|
60 (20)
|
3
|
14 (5)
|
Tumor histology
|
|
SCC
|
287 (94)
|
Others
|
18 (6)
|
Smoking status
|
|
Never
|
36 (12)
|
Past
|
200 (66)
|
Current
|
69 (23)
|
Habitual alcoholic consumption
|
|
Yes
|
121 (40)
|
No
|
184 (60)
|
Distance from the hospital
|
|
< 10 km
|
92 (30)
|
≥ 10 km
|
213 (70)
|
Family members in the same household
|
|
Yes
|
258 (85)
|
No
|
47 (15)
|
Use of ACEi or ARB
|
|
ARB
|
53 (17)
|
ACEi
|
2 (1)
|
No
|
250 (82)
|
Use of PPI or H
2 blocker
|
|
Yes
|
163 (53)
|
No
|
142 (47)
|
Oral hygiene before treatment
|
|
Good
|
100 (33)
|
Poor
|
193 (63)
|
Unknown
|
12 (4)
|
Coexistence of other malignancies
|
|
Yes
|
36 (12)
|
No
|
269 (88)
|
Comorbidity index
|
|
0
|
233 (76)
|
≥ 1
|
72 (24)
|
Serum albumin before treatment
|
|
Within normal limits
|
259 (85)
|
Less than normal range
|
46 (15)
|
Hemoglobin before treatment
|
|
Within normal limits
|
212 (70)
|
Less than normal range
|
93 (30)
|
Use of sleeping pills at the end of treatment
|
|
Yes
|
210 (69)
|
No
|
95 (31)
|
Main feeding at the end of treatment
|
|
Oral
|
127 (42)
|
Non-oral
|
178 (58)
|
Presence of gastrostomy during the treatment
|
|
Yes
|
173 (57)
|
No
|
132 (43)
|
Induction chemotherapy
|
|
Yes
|
76 (25)
|
No
|
229 (75)
|
Concurrent chemotherapy regimen
|
|
CDDP-based
|
235 (77)
|
CBDCA-based
|
42 (14)
|
Cetuximab
|
28 (9)
|
Radiation technique
|
|
Conventional 3D-CRT
|
241 (79)
|
IMRT
|
64 (21)
|
Irradiation field
|
|
Primary lesion alone
|
40 (13)
|
Hemi neck
|
19 (6)
|
Whole neck
|
246 (81)
|
Treatment efficacy
|
|
CR
|
199 (65)
|
Non-CR
|
106 (35)
|
Body weight loss after treatment
|
|
< 10%
|
178 (58)
|
≥ 10%
|
127 (42)
|
Serum albumin decreasing post-treatment
|
|
< 20%
|
114 (37)
|
≥ 20%
|
191 (63)
|
Hemoglobin decreasing post-treatment
|
|
< 30%
|
138 (45)
|
≥ 30%
|
167 (55)
|
The worst mucositis grade during treatment
|
|
0
|
3 (1)
|
1
|
16 (5)
|
2
|
102 (33)
|
3
|
182 (60)
|
4
|
2 (1)
|
The worst dysphagia grade during treatment
|
|
0
|
12 (4)
|
1
|
84 (28)
|
2
|
76 (25)
|
3
|
133 (44)
|
4
|
0
|
Resection of primary lesion post-CRT or -BRT
|
|
Yes
|
30 (10)
|
No
|
275 (90)
|
Neck dissection post-CRT or -BRT
|
|
Radical neck dissection
|
0
|
Modified radical neck dissection
|
1 (1)
|
Selective neck dissection
|
44 (14)
|
Univariate analysis
|
Multivariate analysis
|
|||
---|---|---|---|---|
Odds ratio (95% CI)
|
P-value
|
Odds ratio (95% CI)
|
P-value
|
|
Age
|
||||
< 65 years old
|
Ref.
|
|||
≥ 65 years old
|
1.71 (0.97–2.99)
|
0.06
|
||
Gender
|
||||
Male
|
1.06 (0.46–2.43)
|
0.89
|
||
Female
|
Ref.
|
|||
ECOG performance status
|
||||
0–1
|
Ref.
|
|||
2–3
|
2.61 (0.89–7.62)
|
0.07
|
||
Body mass index
|
||||
< 18.5
|
Ref.
|
|||
18.5–25
|
0.87 (0.41–1.87)
|
0.73
|
||
≥ 25
|
0.71 (0.27–1.83)
|
0.48
|
||
Primary site
|
||||
Larynx
|
Ref.
|
|||
Nasopharynx
|
1.21 (0.32–4.55)
|
0.77
|
||
Hypopharynx
|
2.07 (0.73–5.83)
|
0.17
|
||
Nasal sinus
|
1.71 (0.36–8.12)
|
0.49
|
||
Oropharynx
|
3.49 (1.23–9.94)
|
0.02
|
1.69 (0.50–5.67)
|
0.39
|
Oral cavity
|
4.44 (1.06–18.7)
|
0.04
|
1.95 (0.38-9.98)
|
0.42
|
T-classification
|
||||
1–2
|
Ref.
|
|||
3–4
|
2.38 (1.32–4.30)
|
0.004
|
1.75 (0.85–3.59)
|
0.12
|
N-classification
|
||||
0–2b
|
Ref.
|
|||
2c–3
|
1.39 (0.75–2.57)
|
0.29
|
||
Tumor histology
|
||||
SCC
|
Ref.
|
|||
Others
|
0.20 (0.02–1.57)
|
0.12
|
||
Smoking status
|
||||
Never
|
Ref.
|
|||
Past
|
0.87 (0.37–2.07)
|
0.76
|
||
Current
|
1.14 (0.43–2.98)
|
0.78
|
||
Habitual alcoholic consumption
|
||||
Yes
|
1.79 (1.00–3.24)
|
0.05
|
2.11 (1.01–4.38)
|
0.04
|
No
|
Ref.
|
|||
Distance from the hospital
|
||||
< 10 km
|
Ref.
|
|||
≥ 10 km
|
0.88 (0.48–1.59)
|
0.67
|
||
Family members in the same household
|
||||
Yes
|
Ref.
|
|||
No
|
1.33 (0.64–2.73)
|
0.44
|
||
Use of ACEi or ARB
|
||||
Yes
|
1.50 (0.76–2.93)
|
0.23
|
||
No
|
Ref.
|
|||
Use of PPI or H
2 blocker
|
||||
Yes
|
1.02 (0.58–1.77)
|
0.94
|
||
No
|
Ref.
|
|||
Oral hygiene before treatment
|
||||
Good
|
Ref.
|
|||
Poor
|
2.63 (1.33–5.21)
|
0.005
|
2.81 (1.28–6.16)
|
0.01
|
Coexistence of other malignancies
|
||||
Yes
|
2.72 (1.30–5.68)
|
0.007
|
3.51 (1.46–8.42)
|
0.005
|
No
|
Ref.
|
|||
Comorbidity index
|
||||
0
|
Ref.
|
|||
≥ 1
|
0.59 (0.29–1.22)
|
0.15
|
||
Serum albumin before treatment
|
||||
Within normal limits
|
Ref.
|
|||
Less than normal range
|
4.60 (2.37–8.95)
|
0.000006
|
2.70 (1.12–6.53)
|
0.02
|
Hemoglobin before treatment
|
||||
Within normal limits
|
Ref.
|
|||
Less than normal range
|
2.62 (1.49–4.61)
|
0.0008
|
1.08 (0.51–2.28)
|
0.84
|
Use of sleeping pills at the end of treatment
|
||||
Yes
|
3.22 (1.83–5.67)
|
0.00005
|
4.39 (2.21–8.74)
|
0.00002
|
No
|
Ref.
|
|||
Main feeding at the end of treatment
|
||||
Oral
|
Ref.
|
|||
Non-oral
|
1.66 (0.93-2.96)
|
0.09
|
||
Presence of gastrostomy during the treatment
|
||||
Yes
|
2.6 (1.41-4.77)
|
0.0018
|
1.58 (0.754-3.31)
|
0.22
|
No
|
Ref.
|
|||
Induction chemotherapy
|
||||
Yes
|
1.20 (0.64–2.23)
|
0.56
|
||
No
|
Ref.
|
|||
Concurrent chemotherapy regimen
|
||||
CDDP-based
|
Ref.
|
|||
CBDCA-based
|
1.01 (0.45–2.25)
|
0.98
|
||
Cetuximab
|
1.01 (0.38–2.62)
|
0.98
|
||
Radiation technique
|
||||
Conventional 3D-CRT
|
1.60 (0.76–3.34)
|
0.21
|
||
IMRT
|
Ref.
|
|||
Irradiation field
|
||||
Primary alone
|
Ref.
|
|||
Hemi neck
|
3.82 (0.43–33.5)
|
0.22
|
||
Whole neck
|
5.43 (0.71–41.6)
|
0.10
|
||
Treatment efficacy
|
||||
CR
|
Ref.
|
|||
non-CR
|
2.56 (1.46–4.48)
|
0.0009
|
1.60 (0.81–3.14)
|
0.17
|
Body weight loss after treatment
|
||||
< 10%
|
Ref.
|
|||
≥ 10%
|
1.26 (0.72–2.19)
|
0.41
|
||
Serum albumin decreasing post-treatment
|
||||
< 20%
|
Ref.
|
|||
≥ 20%
|
1.12 (0.63–1.97)
|
0.71
|
||
Hemoglobin decreasing post-treatment
|
||||
< 30%
|
Ref.
|
|||
≥ 30%
|
1.31 (0.75–2.29)
|
0.33
|
||
The worst mucositis grade during treatment
|
||||
0–2
|
Ref.
|
|||
3–4
|
0.91 (0.51–1.58)
|
0.72
|
||
The worst dysphagia grade during treatment
|
||||
0–2
|
Ref.
|
|||
3–4
|
0.59 (0.33–1.05)
|
0.07
|